pre-exposure prophylaxis (PrEP)
Second case of unintended HIV transmission during HIV cure study prompts questions about PrEP provision
ACCESS PrEP blog series: Oral PrEP health providers have their say - opinions, thoughts and experiences
The development of topical inserts for the prevention of sexually transmitted infections (STIs), particularly human immunodeficiency virus (HIV), represents a promising alternative to oral and parenteral pre-exposure prophylaxis (PrEP) dosage forms. They may be used for vaginal and/or rectal administration of a variety of agents with antiviral activity. Topical inserts deliver drugs to the portal of viral entry, i.e., the genital or rectal mucosa, with low systemic exposure, and therefore are safer and have fewer side effects than systemic PrEP agents.
There’s power in OPTIONS: Recent developments from the project that is optimizing HIV prevention technology introduction on schedule
“We know that life-changing HIV prevention solutions are available, but it’s critical to think strategically about how an innovation like PrEP is meaningful to our priority users. By understanding who our user is, what is important to them, and how PrEP can be positioned as useful and beneficial, we can help create an enabling environment for PrEP uptake.” - Briana Ferrigno, McCann Health
Oral pre-exposure prophylaxis (PrEP) is a new HIV prevention method that offers more than 90 percent protection when taken correctly. The OPTIONS Consortium, in collaboration with the South African National Department of Health, created five short, powerful videos that encourage PrEP as an acceptable HIV prevention method for adolescent girls and young women.